Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr 15;27(8):836-52.
doi: 10.1101/gad.217406.113.

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

Affiliations
Review

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

Julie-Aurore Losman et al. Genes Dev. .

Abstract

Mutations in metabolic enzymes, including isocitrate dehydrogenase 1 (IDH1) and IDH2, in cancer strongly implicate altered metabolism in tumorigenesis. IDH1 and IDH2 catalyze the interconversion of isocitrate and 2-oxoglutarate (2OG). 2OG is a TCA cycle intermediate and an essential cofactor for many enzymes, including JmjC domain-containing histone demethylases, TET 5-methylcytosine hydroxylases, and EglN prolyl-4-hydroxylases. Cancer-associated IDH mutations alter the enzymes such that they reduce 2OG to the structurally similar metabolite (R)-2-hydroxyglutarate [(R)-2HG]. Here we review what is known about the molecular mechanisms of transformation by mutant IDH and discuss their implications for the development of targeted therapies to treat IDH mutant malignancies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The role of the IDH family of enzymes in the TCA cycle. Shown here are the mitochondrial and cytoplasmic reactions that involve IDH; also shown are the principal mechanisms of entry of glucose and glutamine-derived carbon molecules into the TCA cycle. IDH1 reversibly catalyzes the NADP+-dependent decarboxylation of isocitrate to 2OG in the cytoplasm, whereas IDH2 mediates the same reaction in the mitochondria. IDH3 catalyzes the NAD+-dependent conversion of isocitrate to 2OG in the mitochondria in a reaction that is irreversible under physiologic conditions. (ACO) Aconitase.
Figure 2.
Figure 2.
Reactions catalyzed by wild-type and mutant IDH1 and IDH2. Wild-type IDH1 and IDH2 catalyze a two-step reaction (indicated by blue arrows). The first step involves the oxidation of isocitrate to the unstable intermediate oxalosuccinate. In this reaction, NADP+ acts as the hydrogen acceptor and is reduced to NADPH. In the second step of the reaction, the β-carboxyl group is released as carbon dioxide (CO2), resulting in production of 2OG. Mutant IDH1 and IDH2 catalyze a single-step reaction (indicated by the purple arrow). In this reaction, NADPH is oxidized to NADP+, with concomitant reduction of 2OG to (R)-2HG. The mutant enzymes are unable to catalyze the carboxylation of (R)-2HG and therefore cannot generate 2OG. 2OG and 2HG are structurally very similar. They differ only in the replacement of the ketone group in 2OG with a hydroxyl group in 2HG.

References

    1. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Lowenberg B, Valk PJ 2010. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood 116: 2122–2126 - PubMed
    1. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, et al. 2009. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114: 144–147 - PMC - PubMed
    1. Abdel-Wahab O, Patel J, Levine RL 2011. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am 25: 1119–1133 - PubMed
    1. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, et al. 2011a. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224: 334–343 - PubMed
    1. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, et al. 2011b. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43: 1262–1265 - PubMed

Publication types